The National Institute for Health and Care Excellence (NICE) in the UK recently added the option of relugolix–estradiol–norethisterone oral therapy for patients in whom other medical and surgical management for endometriosis has failed.

Relugolix is a GnRH antagonist which works by competitively binding to receptors with rapid suppression of pituitary gonadotrophin hormone production. This results in a decrease in oestrogen levels. The hypoestrogenic state provides symptom relief, whilst adverse effects such as vasomotor symptoms and decreased bone mineral density are minimised by “add-back” therapy of estradiol and norethisterone in the same preparation.

Read communication from NICE.